Oramed Pharmaceuticals Surpasses $100 Million in Returns Following New Payment from Scilex Holdings

Oramed Pharmaceuticals Reports Significant Financial Milestone

Oramed Pharmaceuticals Inc., a pioneering company in oral delivery solutions for drugs, has announced a significant financial achievement by receiving an $18 million payment from Scilex Holdings Inc. This payment fulfills obligations under the Option Agreement, bringing Oramed's total returns from its initial $99.5 million investment in Scilex to an impressive $118 million. This achievement signals strong performance from its investment portfolio and highlights the company's ongoing growth trajectory.

The recent payment allows Oramed to maintain a total of $39 million in outstanding debts with Scilex, which includes both convertible notes and warrants. Specifically, Oramed retains a $27 million note and a $12 million convertible note. The latter can be converted into Scilex equity at a share price of $36, providing additional potential for future gains. If the conversion does not occur, the note is scheduled to be repaid in quarterly installments through October 2026.

In addition to this positive news, Oramed's Board of Directors has approved a cash dividend of $0.25 per share as a means of rewarding shareholders. This dividend's ex-dividend date is set for January 16, 2026, with an anticipated disbursement on January 26, 2026. Based on the current number of outstanding shares, the total dividend distribution is projected to reach approximately $10.5 million, highlighting the company's robust financial health and commitment to its shareholders.

Overview of Oramed Pharmaceuticals

Oramed Pharmaceuticals is at the forefront of transforming drug delivery, particularly focusing on oral delivery solutions designed for medications that are typically administered via injection. Their innovative Protein Oral Delivery (POD™) technology aims to maintain drug integrity while improving absorption rates. As a clinical-stage company, Oramed is committed to enhancing patient care through its leading-edge technology while also building a diverse investment portfolio.

The company is currently working on refining its oral insulin program, which is poised to address significant needs in diabetes management—a condition that affects millions worldwide. Oramed's advancements in research and development demonstrate its potential to revolutionize how medications are delivered, ultimately improving patient outcomes.

Future Outlook

Oramed's recent financial gains and successful investments position it well for future growth. The ongoing developments regarding its relationship with Scilex not only enhance the company's financial status but also strengthen its portfolio, providing multiple avenues for the realization of expected returns.

As Oramed continues to explore various partnerships and market opportunities, the combination of its leading technology and strategic investment endeavors suggests a promising future. Investors and stakeholders will be keenly watching the developments that follow the recent announcements, particularly in anticipation of the dividends and further innovation in drug delivery technologies.

To learn more about Oramed Pharmaceuticals and its pioneering work, visit www.oramed.com.

Disclaimer

This article contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Such statements involve risks that may cause actual results to differ materially from those anticipated. Please consider these uncertainties when evaluating future projections. Further, Oramed has no obligation to publicly update any forward-looking statements after this release.